Insider · CIK 0001796787
Asit Parikh
Files at PHAT (Phathom Pharmaceuticals, Inc.). First filing Dec 16, 2024, latest May 8, 2025.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
PHAT: Phathom Pharmaceuticals, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 44Moderate | Phathom Pharmaceuticals, Inc. | $25k 10,000 shares | +12% | 0% from low-88% from high | |
| 35Weak | Phathom Pharmaceuticals, Inc. | $81k 10,000 shares | +15% | - |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Dec 19, 2025 | PHAT Phathom Pharmaceuticals, Inc. | MOption exercise Common Stock | +8,750 | $10.30 | $90k | 122,250 | Dec 23, 2025 |
| Dec 19, 2025 | PHAT Phathom Pharmaceuticals, Inc. | MOption exercise Common Stock (Right to Buy)derivative | -8,750 | $0.00 | $0 | 8,750 | Dec 23, 2025 |
| Jun 3, 2025 | PHAT Phathom Pharmaceuticals, Inc. | AGrant or award Common Stock | +10,500 | $0.00 | $0 | 113,500 | Jun 5, 2025 |
| Jun 3, 2025 | PHAT Phathom Pharmaceuticals, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +17,500 | $0.00 | $0 | 17,500 | Jun 5, 2025 |
| May 6, 2025 | PHAT Phathom Pharmaceuticals, Inc. | POpen-market purchase Common Stock | +5,000 | $2.60 | $13k | 90,500 | May 8, 2025 |
| May 7, 2025 | PHAT Phathom Pharmaceuticals, Inc. | POpen-market purchase Common Stock | +5,000 | $2.40 | $12k | 95,500 | May 8, 2025 |
| Dec 13, 2024 | PHAT Phathom Pharmaceuticals, Inc. | POpen-market purchase Common Stock | +10,000 | $8.12 | $81k | 75,500 | Dec 16, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.